Dr. Reddy’s launches generic Zemplar injection

HYDERABAD, India and PRINCETON, N.J. — Dr. Reddy’s Laboratories on Monday announced the U.S. launch of its generic of Zemplar (paricalcitol) injection. The drug is indicated to treat and prevent secondary hyperparathyroidism associated with chronic kidney disease stage 5. 

 

The drug had about $22.5 million in U.S. sales for the 12 months ended July 2016, according to IMS Health. The injection will be available from Dr. Reddy’s in 2-, 5- and 10-mcg dosage strengths.